Table 1.
Association of SLC1A5 protein expression and clinicopathological parameters in luminal breast cancer
| SLC1A5 expression | P | P* | ||
|---|---|---|---|---|
| Low No. (%) | High No. (%) | |||
| Age | 0.02 | 0.03 | ||
| < 50 | 244 (57.3) | 182 (42.7) | ||
| ≥ 50 | 598 (63.6) | 342 (36.4) | ||
| Tumor size (cm) | 0.002 | 0.003 | ||
| < 2 cm | 490 (65.4) | 259 (34.6) | ||
| ≥ 2 cm | 352 (57.1) | 265 (42.9) | ||
| Tumor grade | 3.97e – 22 | < 0.0001 | ||
| 1 | 248 (78.7) | 67 (21.3) | ||
| 2 | 377 (65.9) | 195 (34.1) | ||
| 3 | 214 (45.1) | 261 (54.9) | ||
| NPI | 5.0e – 13 | < 0.0001 | ||
| GPG | 404 (73.1) | 149 (26.9) | ||
| MPG | 357 (56) | 281 (44) | ||
| PPG | 81 (46.3) | 94 (53.7) | ||
| Nodal stage | 0.007 | 0.01 | ||
| 1 | 556 (64.8) | 302 (35.2) | ||
| 2 | 229 (56.3) | 178 (43.7) | ||
| 3 | 54 (55.7) | 43 (44.3) | ||
| Vascular invasion | 1.17e – 10 | < 0.0001 | ||
| Negative | 631 (67.4) | 305 (32.6) | ||
| Positive | 207 (49.1) | 215 (50.9) | ||
| Endocrine therapy | 0.001 | 0.002 | ||
| No | 437 (68.5) | 201 (31.5) | ||
| Yes | 307 (59.3) | 211 (40.7) | ||
| Progesterone receptor | 0.12 | 0.13 | ||
| Negative | 161 (57.3) | 120 (42.7) | ||
| Positive | 637 (62.3) | 385 (37.7) | ||
| Ki67 | 0.03 | 0.038 | ||
| Negative | 231 (65.3) | 123 (34.7) | ||
| Positive | 343 (58.3) | 245 (41.7) | ||
GPG Good prognostic group, MPG Moderate prognostic group, PPG Poor prognostic group
P* Adjusted P values